Drug class · Oncology & immunology
Kinase inhibitors Drug Codes & NDCs
Small-molecule drugs that inhibit one or more protein kinases. Most are oral products dispensed by pharmacies.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ojjaaramomelotinib | Momelotinib dihydrochloride monohydrate 200 mg/1 | TabletOral | GlaxoSmithKline LLC | 81864-101 |
| Ojjaaramomelotinib | Momelotinib dihydrochloride monohydrate 150 mg/1 | TabletOral | GlaxoSmithKline LLC | 81864-102 |
| Ojjaaramomelotinib | Momelotinib dihydrochloride monohydrate 100 mg/1 | TabletOral | GlaxoSmithKline LLC | 81864-103 |
| Olumiantbaricitinib | Baricitinib 2 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4182 |
| Olumiantbaricitinib | Baricitinib 4 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4479 |
| Olumiantbaricitinib | Baricitinib 1 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4732 |
| Opzeluraruxolitinib | Ruxolitinib phosphate 15 mg/g | CreamTopical | Incyte Corporation | 50881-007 |
| Pazopanib | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | Teva Pharmaceuticals, Inc. | 0480-4184 |
| pazopanibpazopanib hydrochloride | Pazopanib hydrochloride 400 mg/1 | Tablet, Film coatedOral | Torrent Pharmaceuticals Limited | 13668-735 |
| Pazopanib | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | AvKARE | 42291-939 |
| Pazopanib | Pazopanib 200 mg/1 | TabletOral | Golden State Medical Supply, Inc. | 51407-872 |
| Pazopanib | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | Aurobindo Pharma Limited | 59651-582 |
| Pazopanib | Pazopanib 200 mg/1 | TabletOral | Apotex Corp. | 60505-4779 |
| Pazopanib | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | SUN PHARMACEUTICAL INDUSTRIES, INC. | 63304-116 |
| pazopanibpazopanib hydrochloride | Pazopanib hydrochloride 200 mg/1 | Tablet, Film coatedOral | Novugen Pharma (USA) LLC. | 82293-022 |
| Pemazyrepemigatinib | Pemigatinib 4.5 mg/1 | TabletOral | Incyte Corporation | 50881-026 |
| Pemazyrepemigatinib | Pemigatinib 9 mg/1 | TabletOral | Incyte Corporation | 50881-027 |
| Pemazyrepemigatinib | Pemigatinib 13.5 mg/1 | TabletOral | Incyte Corporation | 50881-028 |
| Phyragodasatinib | Dasatinib 20 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-151 |
| Phyragodasatinib | Dasatinib 50 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-152 |
| Phyragodasatinib | Dasatinib 70 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-153 |
| Phyragodasatinib | Dasatinib 80 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-154 |
| Phyragodasatinib | Dasatinib 100 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-155 |
| Phyragodasatinib | Dasatinib 140 mg/1 | TabletOral | Cycle Pharmaceuticals Ltd | 70709-156 |
| Qinlockripretinib | Ripretinib 50 mg/1 | TabletOral | Deciphera Pharmaceuticals, LLC | 73207-101 |